A novel FoxD3 Variant Is Associated With Vitiligo and Elevated Thyroid Auto-Antibodies

• Published in: The journal of clinical endocrinology and metabolism 2015-10, Vol.100 (10), p.E1335-E1342
• Main Authors: Schunter, Jo Ana, Löffler, Dennis, Wiesner, Tobias, Kovacs, Peter, Badenhoop, Klaus, Aust, Gabriela, Tönjes, Anke, Müller, Peter, Baber, Ronny, Simon, Jan C, Führer, Dagmar, Pfäffle, Roland W, Thiery, Joachim, Stumvoll, Michael, Kiess, Wieland, Kratzsch, Jürgen, Körner, Antje
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Autoantibodies - blood; Female; Forkhead Transcription Factors - genetics; Genetic Predisposition to Disease; Humans; Iodide Peroxidase - immunology; Male; Middle Aged; Promoter Regions, Genetic; Thyroglobulin - immunology; Thyroiditis, Autoimmune - blood; Thyroiditis, Autoimmune - genetics; Thyroiditis, Autoimmune - immunology; Vitiligo - blood; Vitiligo - genetics; Vitiligo - immunology; Young Adult
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.2015-2126

Context: Vitiligo frequently coincides with autoimmune endocrinopathies, particularly Hashimoto's thyroiditis (HT). Genetic susceptibility may underlie this coincident occurrence. One candidate region is the autoimmunity susceptibility locus on chromosome 1, which encompasses forkhead transcription factor D3 (FoxD3), a gene involved in embryonal melanogenesis. We identified a promotor variant (rs78645479) in an index case of vitiligo + HT + candidiasis and evaluated its clinical and functional relevance. Design: We genotyped 281 patients with variable autoimmune endocrinopathies: HT, Graves' disease (GD), type 1 diabetes (T1D), Addison's disease (AD), autoimmune polyglandular syndrome (APS), and/or vitiligo and 1858 controls. Furthermore, we experimentally assessed the effect of the variant on promotor activity and assessed the expression of FoxD3 in human thyroid tissue samples. Results: Patients with vitiligo had a higher frequency of the risk allele (30%) compared with healthy controls (18.2%). In addition, the variant was associated with the incidence of elevated anti-TPO antibodies and anti-Tg antibodies, but not with TSH, FT3, or FT4 levels and also not with GD, T1D, AD, or APS. Functionally, the variant increased transcriptional activity in Jurkat and in Hek293 cells. We confirmed gene expression of FoxD3 in human thyroid tissue, which seemed elevated in thyroid tissue samples of some patients with GD and nonautoimmune goiter but not in patients with HT. Conclusion: In addition to a possible association of rs78645479 in FoxD3 with vitiligo, our data on the association of this FoxD3 variant with thyroid autoantibodies suggest a potential involvement of FoxD3 in thyroid immunoregulation.